1513.HK

Livzon Pharmaceutical Group Inc. 1513.HK

Net profit

EBITDA

P/E Ratio

Capitalization

Performance

Periode 1513.HK 0867.HK 3320.HK 0512.HK 3933.HK 0874.HK 6821.HK 2696.HK 1548.HK 1066.HK
6M 26.65 % 82.04 % -2.46 % 49.28 % 4.26 % 8.62 % 112.88 % 115.02 % 54.04 % 1.99 %
YTD 21.94 % 80.32 % -13.79 % 80.43 % 8.01 % 1.18 % 83.32 % 210.64 % 62.97 % 28.54 %
1Y 16.93 % 57.23 % -19.08 % 77.35 % 24.02 % -5.71 % 63.40 % 225.89 % 35.76 % 12.83 %
3Y 54.43 % 46.39 % -16.37 % 117.85 % 276.64 % 0.73 % 3.15 % 461.54 % -12.55 % -53.85 %
5Y -10.55 % 55.94 % 21.17 % 26.52 % 84.64 % -8.11 % -65.28 % 69.77 % 37.63 % -64.46 %
10Y 79.79 % 26.23 % -47.28 % 2 289.45 % 204.61 % -17.00 % -65.28 % 47.62 % 1 113.64 % -1.92 %
From the beginning 83.31 % 344.52 % -47.28 % 3 544.67 % 299.40 % 2 096.34 % -65.28 % 47.62 % 1 113.64 % 3 117.14 %

Dividend

Livzon Pharmaceutical Group Inc.

China Medical System Holdings Limited

China Resources Pharmaceutical Group Limited

Grand Pharmaceutical Group Limited

The United Laboratories International Holdings Limited

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited

Asymchem Laboratories (Tianjin) Co., Ltd.

Genscript Biotech Corporation

Shandong Weigao Group Medical Polymer Company Limited